infliximab-qbtx Ixifi

Selected indexed studies

• Biosimilar infliximab administration for the management of acute graft-versus-host disease. (J Oncol Pharm Pract, 2020) [PMID:32356680]
• The 'totality-of-the-evidence' approach in the development of PF-06438179/GP1111, an infliximab biosimilar, and in support of its use in all indications of the reference product. (Ther Adv Gastroenterol, 2019) [PMID:31223341]

_Worker-drafted node — pending editorial review._